Fujifilm Technical Papers with Preclinical Findings Demonstrate the Potential Value of Liposomal Therapeutics
June 9, 2020
CAMBRIDGE, Mass. – FUJIFILM Pharmaceuticals U.S.A., Inc. a wholly owned U.S. subsidiary of FUJIFILM Holdings America Corporation, has published three new technical papers highlighting animal study results of liposomes as a delivery agent to enhance anti-cancer therapeutics for solid-tumors. Each technical paper highlights preclinical study data which demonstrates increased pharmacological efficacy of liposomes coupled with anti-cancer agents.
Artificially constructed from the same organic phospholipids that make up cells and bio-membranes, liposomes are a drug delivery solution that can carry anti-cancer agents to tumors through the enhanced permeability and retention (EPR) effect.
The data presented in each technical paper comes from researchers, scientists and clinical partners who have presented their work at meetings of the American Association for Cancer Research and the European Organisation for Research and Treatment of Cancer. The three newly published technical papers are:
- Liposomes improving efficacy of anti-cancer agent — FF-10832 A preclinical study that demonstrates that the anti-cancer agent encapsulated in liposome formulation increased half-life and improved survival rate, compared to the unencapsulated anti-cancer agent.
- Exploring liposome as a solution for drug delivery challenges — FF-10850: A preclinical study that demonstrates the potential of Fujifilm’s liposomal drug candidate to suppress tumor growth at lower doses compared to the non-liposomal formulation.
- FUJIFILM liposomes with immune checkpoint inhibitors: Two preclinical studies using FF-10832 and FF-10850 in combination with immune checkpoint inhibitors demonstrate delay of tumor growth compared to immune checkpoint inhibitor monotherapies.
Fujifilm formulates liposomes harnessing nano-dispersion technologies developed over 80 years of photo-film manufacturing. Utilizing its liposome formulation technology, Fujifilm is dedicated to collaborating with partners to bring new therapeutic options to the market.
“The effectiveness of current cancer therapies can be limited due to lack of stability in blood and poor targeting. Liposomes, as a drug delivery solution, could help cancer therapies reach their full potential -- bringing new hope to patients,” said Mikihiko Kato, President, FUJIFILM Pharmaceuticals U.S.A., Inc. “With our sights set on helping patients along the care pathway spectrum, Fujifilm has made the significant investment required in research and clinical development to enhance efficacy of existing cancer therapies.”
The technical papers are available for download on the new FUJIFILM Pharmaceuticals U.S.A., Inc. website: www.fujifilmpharma.com.
Established in 2010, FUJIFILM Pharmaceuticals U.S.A., Inc. is based in Boston, Massachusetts, and specializes in clinical research and development of pharmaceutical products. FUJIFILM Pharmaceuticals U.S.A., Inc. strives to contribute to the further development of global health care through new drug development of unique therapeutic compounds, to combat illnesses such as Alzheimer’s, cancer and infectious diseases.
FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com
All product and company names herein may be trademarks of their registered owners.